2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2968 Coordinated degranulation and netosis by PMN-MDSCs impair CD8⁺ T cell responses in Waldenström macroglobulinemia

Prithviraj Mukherjee, PhD, MS, Vaishali Bhardwaj, PhD2, Zhi-Zhang Yang, MD3, Xinyi Tang, MD, PhD4, Patrizia Mondello, MD, PhD5, Stephen Maxted Ansell, MD, PhD6
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States

Relapse in Waldenström macroglobulinemia (WM) is considered almost inevitable, occurring even after remissions that exceed 15 years, and a tumor-associated ineffective immune response accounts in part for the lack of a sustained response. Our previous work showed that the BM aspirates of symptomatic WM patients are enriched for CD66b+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), which were also shown to suppress CD8+ CD25+ T cells in co-culture assays, thereby contributing to a reduced time to next treatment (TTNT). Given their close ontogenetic relationship to neutrophils, we hypothesized that PMN-MDSC-mediated suppression contributes to the ineffective immune response and operates through two concurrent mechanisms namely degranulation and NETosis, a regulated neutrophil effector mechanism in which decondensed web-like chromatin neutrophil extracellular traps (NETs) are released extracellularly decorated with cytoplasmic proteins.

CITEseq analysis (n=5, 3-unreated/symptomatic WM and 2- normal bone marrow) identified a marked enrichment of degranulation and NETosis-associated proteins in the PMN-MDSCs. The differential gene expression analysis between PMN-MDSCs (CD66b+) and M-MDSCs (CD66b-) showed significantly enriched genes were histone family members H1-5 (avg_log2FC=1.54) and H4C3 (avg_log2FC=2.76) consistent with increased chromatin remodeling and NET release. We also found the expression of peptidyl arginine deiminase 4 (PAD4) in PMN-MDSCs subset, an enzyme specifically responsible for citrullination of nuclear histones which further supported enhanced chromatin re-organization and epigenetic regulation within the CD66b? phenotype. Canonical neutrophil granule and NET-associated proteins, including myeloperoxidase (MPO, avg_log2 FC=3.25), neutrophil elastase (ELANE, avg_log2 FC=1.15), and azurocidin 1 (AZU1, avg_log2 FC=1.52) were also significantly upregulated in CD66b? cells. Comparative flow cytometric analysis demonstrated a marked increase in CitH3-positive PMN-MDSC phenotype (~90%) in the patient sample relative to patient neutrophils (~ 58% , p = 0.003). Additionally, we found the presence of azurophilic-myloperoxidase (primary), specific- lactoferrin, lysozyme (secondary), and gelatinase MMP9, ficolin-1 (tertiary) granules in PMN-MDSCs, indicating that these cells retain the full structural machinery for regulated exocytosis. Consistent with this granule content, PMN-MDSCs express the corresponding degranulation receptors, including G-protein-coupled receptors (CXCR2, CCR2, CXCR3, BLTR), Fcγ receptors (CD32A/B), and the C5a complement receptor (C5AR1). CXCR3 showed significantly higher expression on PMN-MDSCs than on autologous patient neutrophils (mean ± SD 158.9 ± 68.0 vs. 2.95 ± 1.82 MFI; n = 3 patients; unpaired t-test, p = 0.017), suggesting heightened sensitivity to the same inflammatory and complement cues present in the WM bone marrow niche. Activated, PMN-MDSCs degranulated rapidly, within 0–2 hours, in response to C5a, GM-CSF, G-CSF, and TNF-α, measured by surface mobilization of CD63 and CD66b by flow cytometry. Notably, release of CD63 granules, the compartment richest in cytotoxic and immunomodulatory content, was restricted to C5a and active CD8? T cell co-culture stimulation. C5a treatment induced a rapid and sustained increase in CD63 surface expression (fold change ≈ 1.3 at 15 min, p ≤ 0.01; ≈1.2 at 30 min, p ≤ 0.01; ≈1.2 at 60 min, p ≤ 0.05), while CD8? T cell co-culture drove a sharper but more transient response (fold change ≈ 1.47 at 15 min, p ≤ 0.05; ≈1.28 at 30 min, p ≤ 0.001; declining to non-significance by 60 min). Time-lapse imaging showed that PMN-MDSCs exhibit a concurrent NETosis program, occurring within the same 0–2 hour time frame as degranulation. NETosis exhibited in our assay involved chromatin release, where PMN-MDSCs maintains cell viability and functionality, conventionally known as vital NETosis.  All five stimuli triggered robust NET formation, and the resulting in CD8 T cell migration interference. Phase confluence was quantified at 3 hours across five experimental conditions. Although all treatment groups exhibited measurable NETosis, C5a and CD8 elicited the greatest response, reaching approximately 70% and >90% NETosis, respectively.

These findings position PMN-MDSC degranulation and NETosis as interconnected therapeutic targets with potential to restore CD8? T-cell infiltration and improve durable disease control in WM.

Vaishali Bhardwaj, PhD: No relevant conflicts of interest to declare.